Study of OTX-TKI implant for moderate to severe NPDR
Part of Eyes & vision clinical trials.
This study tests an eye implant (OTX-TKI) that slowly releases a medicine to slow or stop worsening of non-proliferative diabetic retinopathy (NPDR) — an early form of diabetic eye disease. It's for people with moderately severe to severe NPDR who haven't had significant treatments like laser or injections in that eye.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 1 or 2 diabetes and your diabetic eye disease is moderately severe to severe (stages called 47 or 53).
- Your vision in the study eye is fairly good — at least 20/40 (can read most of an eye chart).
- You have no diabetic macular edema (swelling) affecting the center of your vision in that eye.
- You haven't had certain prior treatments (like laser or anti-VEGF injections) in the study eye recently or at all.
- You are 18 or older and willing to follow study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ANXV (Annexin A5) to see if it is safe and can help people with diabetic retinopathy or a recent retinal vein occlusion. The goal is to reduce eye damage and improve vision.
This study follows people who completed an earlier 2-year trial of OTX-TKI, a small implant placed in the eye to treat wet age-related macular degeneration (a condition causing vision loss). Researchers want to make sure the treatment remains safe over time.
This study tests whether using a special eye scan (OCTA) to guide targeted laser treatment can slow down the progression of areas with poor blood flow in the retina of people with diabetic retinopathy. The goal is to prevent the condition from getting worse and help preserve your vision.
This trial tests a new medicine, RRG001, given after vitrectomy surgery for severe diabetic eye disease. It aims to see if the drug is safe and helps prevent vision loss.
This is an early-stage safety study testing a new medicine injected directly into the eye to treat diabetic retinopathy (damage to blood vessels in the retina caused by diabetes). The study checks if the medicine is safe and how the body processes it.
This trial checks how well corneal endothelial cells (cells that help keep the cornea clear) do in people with neovascular age-related macular degeneration (nAMD) who are treated with a port-delivery implant that releases ranibizumab. It also helps doctors understand whether this method changes corneal health and stays safe while controlling the eye disease.
Hear when a new Non-Proliferative Diabetic Retinopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.